News and analysis on diagnostic technologies and applications.
The firm has joined forces with AstraZeneca, the IASLC, and the Global Lung Cancer Coalition, with a goal to double five-year survival rates by 2025.
Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
Practical, technological, and systemic challenges are putting pathologists in tough positions, facing competing demands for molecular analysis of limited biological samples.
